Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH CML 2022 | Ponatinib versus ascimininib in the third-line treatment of CML

Jorge Cortes • 21 Oct 2022

ESH CML 2022

Chronic Myeloid Leukemia Leukemia Asciminib Ponatinib

Jorge Cortes, MD, Augusta University, Augusta, GA, compares and contrasts the use of ponatinib and asciminib in the third-line treatment of patients with chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.

Key emerging trials in CML and the importance of improving treatment-free remission rates

Jorge Cortes • 7 Sep 2023

Social determinants of health & their impact on patients with hematological malignancies

Jorge Cortes • 7 Sep 2023

Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status

Jorge Cortes • 7 Sep 2023

Exciting updates in the field of CML: disease pathophysiology & novel agents

Jorge Cortes • 7 Sep 2023

Related Videos

Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies

Florent Malard • 11 Apr 2024

Investigating mutation order in AML using single-cell sequencing

Ravindra Majeti • 8 Apr 2024

An epitope editing approach to enable the use of targeted immunotherapy in AML

Gabriele Casirati • 9 Apr 2024

Developing LSC-targeting agents in AML: progress and current therapeutic capacity

Ravindra Majeti • 8 Apr 2024